Role of survival Post-Progression in phase III trials of systemic chemotherapy in advanced Non-Small-Cell lung cancer: A systemic review

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Hotta, Katsuyuki ^a   Kiura, Katsuyuki ^a   Fujiwara, Yoshiro ^a   Takigawa, Nagio ^a   Hisamoto, Akiko ^a   Ichihara, Eiki ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SURVIVAL POST PROGRESSION; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREND STUDY; LUNG TUMOR; MORTALITY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 81255195789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026646     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
2. NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625.
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, et al. (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 3852-3859.
4. Hotta K, Matsuo K, (2007) Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2: 96.
5. Hotta K, Fujiwara Y, Matsuo K, et al. (2007) Recent improvement in the survival of patients with advanced non-small-cell lung cancer enrolled in phase III trials of first-line systemic chemotherapy. Cancer 109: 939-948.
6. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
7. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, et al. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234.
8. Hotta K, Ueoka H, (2005) New cytotoxic agents: a review of the literature. Crit Rev Oncol Hematol 55: 45-65.
9. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103.
10. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597.
11. Kim ES, et al. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818.
12. Shepherd FA, Rodrigues Pereira J, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
13. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
14. Soria JC, Massard C, Le Chevalier T, (2010) Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 21: 2324-2332.
15. Broglio KR, Berry DA, (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101: 1642-1649.
16. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.
17. Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y, (2006) Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol 11: 167-175.
18. Hotta K, Kiura K, Takigawa N, Fujiwara Y, Tabata M, et al. (2010) Progression-free survival (PFS) and overall survival (OS) in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol (abstr #7624).
19. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, et al. (2009) Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 4: 311-317.
20. Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, et al. (2010) Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Ann Oncol (in press).
21. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, et al. (2009) Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 4: e7835.
22. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Oze I, et al. (2009) Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann Oncol 20: 829-834.
23. Hotta K, Fujiwara Y, Kiura K, Tabata M, Takigawa N, et al. (2007) Relationship between response rate and survival in over 50,000 patients of advanced non-small-cell lung cancer treated with systemic chemotherapy. J Thorac Oncol 2: 402-407.
24. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, et al. (2004) Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22: 3860-3867.
25. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, et al. (2004) Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15: 1782-1789.
26. Saad ED, Katz A, Buyse M, (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 28: 1958-1962.
27. Bowater RJ, Bridge LJ, Lilford RJ, (2008) The relationship between progression-free and post-progression survival in treating four types of metastatic cancer. Cancer Letters 262: 48-53.
28. Di Leo A, Bleiberg H, Buyse M, (2003) Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 21: 2045-2047.
29. Yothers G, (2007) Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 25: 5153-5154.
30. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, et al. (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25: 5218-5224.
31. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, et al. (2001) Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91: 2033-2038.
32. Piedbois P, Buyse M, (2004) Meta-analysis based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 22: 3839-3841.